Skip to main content

Table 3 Multivariate regression models for the diagnosis of neurodegenerative disorders

From: Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia

Group comparisons Biomarkers AUC (95% CI) Specificity Sensitivity
AD vs. OND t-tau, p-tau, Aβ1–42 0.98 (0.96–1.00) 0.88 1.00
DLB vs. OND Age, Aβ1–42 0.79 (0.66–0.92) 0.90 0.69
PD vs. OND Age, t-tau 0.72 (0.57–0.87) 0.58 0.90
PDD vs. OND Age, Aβ1–42 0.81 (0.68–0.94) 0.69 0.95
AD vs. DLB p-tau, FABP3 0.92 (0.86–0.98) 0.76 0.95
AD vs. PDD p-tau, a-syn, FABP3 0.96 (0.91–1.00) 0.88 1.00
AD vs. PD t-tau, α-syn 0.99 (0.97–1.00) 0.97 0.93
DLB vs. PDD t-tau 0.63 (0.46–0.79) 0.85 0.42
DLB vs. PD t-tau, a-syn, FABP3 0.92 (0.84–0.99) 0.95 0.80
PD vs. PDD Age, t-tau, a-syn, FABP3 0.91 (0.84–0.99) 0.77 0.95
  1. Abbreviations: Aβ 1–42 Amyloid-β peptide 1–42, AD Alzheimer’s disease, DLB Dementia with Lewy bodies, FABP3 Fatty acid binding protein 3, heart type, OND Other neurological diseases, PD Parkinson’s disease, PDD Parkinson’s disease with dementia, p-tau 181 Phosphorylated tau 181, α-syn α-Synuclein, t-tau Total tau
  2. We used logistic regression to analyze which combination of biomarkers would be most useful to distinguish each disease from the control group (OND) and for differential diagnosis. Demographic variables such as age and sex were included to assess their influence on the final models. Several models were fitted using different combination of biomarkers and potential confounders; only the best performing model for each comparison is reported, according to AUC, sensitivity, and specificity